サンプル依頼リスト カート
  • English
  • Korean
表紙：北米のオピオイドの市場規模、シェア、動向分析レポート：製品別、用途別、地域別、セグメント別予測、2023年～2030年
市場調査レポート
商品コード
1362903

北米のオピオイドの市場規模、シェア、動向分析レポート：製品別、用途別、地域別、セグメント別予測、2023年～2030年

North America Opioids Market Size, Share & Trends Analysis Report By Product (IR/Short-acting, ER/Long-acting), By Application (Pain Relief, Anesthesia,Cough Suppression), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
北米のオピオイドの市場規模、シェア、動向分析レポート：製品別、用途別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年09月06日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米のオピオイド市場の成長と動向

Grand View Research, Inc.の最新調査によると、北米のオピオイド市場は2023年から2030年にかけて推定CAGR 0.8％で成長し、2030年には153億米ドルに達する見込みです。

良好な規制とヘルスケア改革は、新しい乱用抑止オピオイドの開発に向けた研究開発と商業化の努力に資する環境を提供し、予測期間中の産業成長を促進します。さらに、主な企業は、薬剤が改ざんされにくいように設計された乱用抑止技術の開発に多額の資金を投入しています。その他の活動としては、オピオイドの簡便な抽出に抵抗する物理的または化学的障壁の使用、抽出時に不快な効果をもたらす忌避剤の製剤への添加、活性型に変換するために酵素活性に依存するオピオイドプロドラッグの製剤化などが挙げられます。これらの

このような耐タンパー性のオピオイド製剤は、誤用の発生を軽減することが期待されます。

オピオイドは慢性疼痛管理の主役であり、さまざまな疼痛状態を緩和するために使用されています。コデインやモルヒネを含むオピオイドは、咳止め薬として頻繁に使用されています。コデインは副作用が少ないため、咳止めのゴールドスタンダードと考えられています。さらに、これらの麻薬は消化管受容体に作用するため、過敏性腸症候群による下痢の治療にも用いられます。さらに、末梢作用性のロペラミドは下痢の抑制によく使用されます。このように、オピオイド市場の有益な成長は、咳、下痢、疼痛を含む多様な症状の管理における用途の広さにあります。

北米のオピオイド市場レポートハイライト

  • 徐放性オピオイドセグメントが2022年に53.8%以上の最大シェアを占める。このセグメントの優位性は、慢性疼痛管理におけるこれらの薬剤の高い使用率と、経皮パッチなどの革新的な剤形の開発に起因します。
  • モルヒネやコデインを含む即効性の剤形の市場シェアは、頻繁な製品回収や使用に伴う重篤な副作用のために低下すると予想されます。
  • 用途別では、疼痛緩和の分野が2022年の売上高で最大のシェアを占めました。化学療法や放射線療法中に引き起こされる大量の痛みが、がん分野でこれらの薬剤の採用が増加している主な要因です。
  • 術後疼痛管理セグメントは、疼痛緩和カテゴリーで最も急成長している用途であると予想されます。手術後の疼痛管理への適用性が高いことから、手術件数の増加が近い将来、オピオイドの分野への浸透を促進すると予想されています。
  • 2022年には米国が95.6％の売上高シェアで市場を独占しました。その主な要因のひとつは、関節リウマチなどの末期症状に臨床的に罹患しやすい高齢者人口の増加が、この市場にプラスの影響を与えていることです。
  • 加えて、外傷や傷害、重篤で慢性的な障害性疾患、手術後の疼痛管理にオピオイドを使用するケースが増加していることも、北米地域の市場成長を後押ししています。
  • カナダは、がん性疼痛、筋骨格系障害、術後疼痛など、様々な疼痛関連疾患の有病率の増加から生じる需要により、予測期間中に1.2%という最も速い成長率で成長すると予想されます。加えて、カナダでは高齢化が進んでおり、オピオイドの需要にさらに貢献しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 北米のオピオイド市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 北米のオピオイド市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 北米のオピオイド：製品の推定・動向分析

  • 北米のオピオイド市場：重要なポイント
  • 北米のオピオイド市場：動向と市場シェア分析、2022年と2030年
  • 即効性/短時間作用型オピオイド
    • 即効性/短時間作用型オピオイド市場推計・予測、2018年から2030年まで
    • コデイン
    • オキシコドン
    • ヒドロコドン
    • フェンタニル
    • モルヒネ
    • ヒドロキシモルホン
    • オキシモルフォン
    • プロポキシフェン
    • その他
  • 徐放性/長時間作用型オピオイド
    • 徐放性/長時間作用型オピオイド市場推計・予測、2018年から2030年まで
    • オキシコドン
    • ヒドロコドン
    • メタドン
    • フェンタニル
    • モルヒネ
    • オキシモルフォン
    • タペンタドール
    • ブプレノルフィン
    • ヒドロモルフォン
    • その他

第5章 北米のオピオイド市場：用途の推定・動向分析

  • 北米のオピオイド市場：重要なポイント
  • 北米のオピオイド市場：動向と市場シェア分析、2022年と2030年
  • 鎮痛剤
  • 麻酔
  • 咳止め
  • 下痢止め
  • 脱依存症

第6章 北米のオピオイド市場：地域の推定・動向分析

  • 地域別の展望
  • 地域別の北米のオピオイド市場：主要なマーケットプレース要点
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Purdue Pharma L.P.
    • Janssen Global Services, LLC
    • Hikma Pharmaceuticals PLC
    • Pfizer Inc.
    • AbbVie Inc.
    • Sanofi
    • Sun Pharmaceutical Industries Ltd.
    • Mallinckrodt Pharmaceuticals
    • Endo Pharmaceuticals
    • Teva Pharmaceutical Industries
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America opioids market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America opioids market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America opioids market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. opioids market, by product, 2018 - 2030 (USD Million)
  • Table 6 U.S. opioids market, by application, 2018 - 2030 (USD Million)
  • Table 7 Canada opioids market, by product, 2018 - 2030 (USD Million)
  • Table 8 Canada opioids market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Opioids: Market outlook
  • Fig. 9 Opioids: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 North America opioids market driver impact
  • Fig. 14 North America opioids market restraint impact
  • Fig. 15 North America opioids market strategic initiatives analysis
  • Fig. 16 North America opioids market: Product movement analysis
  • Fig. 17 North America opioids market: Product outlook and key takeaways
  • Fig. 18 Immediate release/ Short acting opioids market estimates and forecasts, 2018 - 2030
  • Fig. 19 Codeine market estimates and forecasts, 2018 - 2030
  • Fig. 20 Oxycodone market estimates and forecasts, 2018 - 2030
  • Fig. 21 Hydrocodone market estimates and forecasts, 2018 - 2030
  • Fig. 22 Fentanyl market estimates and forecasts, 2018 - 2030
  • Fig. 23 Morphine market estimates and forecasts, 2018 - 2030
  • Fig. 24 Hydroxymorphone market estimates and forecasts, 2018 - 2030
  • Fig. 25 Oxymorphone market estimates and forecasts, 2018 - 2030
  • Fig. 26 Propoxyphene market estimates and forecasts, 2018 - 2030
  • Fig. 27 Others market estimates and forecasts, 2018 - 2030
  • Fig. 28 North America opioids market: Application movement analysis
  • Fig. 29 North America opioids market: Application outlook and key takeaways
  • Fig. 30 Extended release/Long acting opioids market estimates and forecasts, 2018 - 2030
  • Fig. 31 Oxycodone market estimates and forecasts, 2018 - 2030
  • Fig. 32 Hydrocodone market estimates and forecasts, 2018 - 2030
  • Fig. 33 Methadone market estimates and forecasts, 2018 - 2030
  • Fig. 34 Fentanyl market estimates and forecasts, 2018 - 2030
  • Fig. 35 Morphine market estimates and forecasts, 2018 - 2030
  • Fig. 36 Oxymorphone market estimates and forecasts, 2018 - 2030
  • Fig. 37 Tapentadol market estimates and forecasts, 2018 - 2030
  • Fig. 38 Buprenorphine market estimates and forecasts, 2018 - 2030
  • Fig. 39 Hydromorphone market estimates and forecasts, 2018 - 2030
  • Fig. 40 Others market estimates and forecasts, 2018 - 2030
  • Fig. 41 North America opioids market: Regional movement analysis
  • Fig. 42 North America opioids market: Regional outlook and key takeaways
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030
  • Fig. 44 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 45 Canada market estimates and forecasts, 2018 - 2030
目次
Product Code: GVR-1-68038-075-0

North America Opioids Market Growth & Trends:

The North America opioids market is expected to reach USD 15.3 billion by 2030, growing at an estimated CAGR of 0.8% from 2023 to 2030, according to a new study by Grand View Research, Inc.. Favorable regulations and healthcare reforms are providing an environment, conducive for research and development as well as commercialization efforts directed toward the development of novel abuse-deterrent opioids, to flourish and drive the industry growth during the forecast period. Furthermore, the key players are deploying large funds in the development of abuse-deterrent technology wherein drugs are designed to be tamper resistant. This is achieved through alterations involving, among others, the use of physical or chemical barriers to resist convenient extraction of the opioids, the addition of an aversive agent to the formulation that would yield an unpleasant effect upon its extraction, and the formulation of opioid prodrugs that are dependent on enzymatic activity in order to be rendered to their active forms. These tamper-resistant opioid drug forms are anticipated to mitigate the incidence of their misuse.

Opioids are the mainstay of chronic pain management that is used to alleviate varied pain conditions. Opiates including codeine and morphine are frequently employed as cough suppression medication. Codeine is considered as a gold standard for cough suppression since it has minimal side effects. Moreover, these narcoticsare used in the treatment of irritable bowel syndrome-induced diarrhea since they act on gastrointestinal receptors. In addition, peripherally acting loperamide is commonly used to suppress diarrhea. Thus, theprofitable growth of the Opioid Market lies in its breadth of applications in the management of diverse conditions including cough, diarrhea, and pain.

North America Opioids Market Report Highlights:

  • The extended-release opioids segment accounted for the largest share over 53.8% in 2022. The dominance of the segment is attributed to the high usage of these drugs for chronic pain management and the development of innovative dosage forms, such as transdermal patches.
  • Market share of the immediate-release dosage forms including morphine and codeine, is expected to decline owing to the frequent product recalls and severe side effects associated with their use.
  • In terms of applications, The pain relief segment dominated the market with the largest revenue share in 2022. The extensive amount of pain caused during chemotherapy and radiotherapy are the primary factors resulting in the increasing incorporation of these drugs in the cancer segment.
  • The post-operative pain management segment is expected to be the fastest growing application in the pain relief category. As a result of their high applicability in post- surgical pain management, the rise in number of surgical procedures is expected to fuel the sector penetration of opioids in the near future.
  • The U.S. dominated the market with the highest revenue share of 95.6% in 2022. One of the major determinants is the growing geriatric population with clinically demonstrated susceptibility to terminal conditions, such as rheumatoid arthritis, is positively impacting this vertical.
  • In addition, the increasing adoption of opioids for pain management related to trauma and injury cases, in severe and chronic disabling diseases, and in cases of post-surgical pain, is driving the growth of the market in the North America region
  • The Canada is expected to grow at the fastest growth rate of 1.2% over the forecast period owing to the demand arising from the increasing prevalence of various pain-related conditions, such as cancer-related pain, musculoskeletal disorders, and post-operative pain. In addition, the growing aging population in Canada has further contributed to the demand for opioids.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Application
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. North America Opioids Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. North America Opioids Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. North America Opioids: Product Estimates & Trend Analysis

  • 4.1. North America Opioids Market: Key Takeaways
  • 4.2. North America Opioids Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Immediate Release/ Short-acting Opioids
    • 4.3.1. Immediate release/ Short acting opioids market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.2. Codeine
      • 4.3.2.1. Codeine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.3. Oxycodone
      • 4.3.3.1. Oxycodone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.4. Hydrocodone
      • 4.3.4.1. Hydrocodone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.5. Fentanyl
      • 4.3.5.1. Fentanyl market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.6. Morphine
      • 4.3.6.1. Morphine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.7. Hydroxymorphone
      • 4.3.7.1. Hydroxymorphone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.8. Oxymorphone
      • 4.3.8.1. Oxymorphone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.9. Propoxyphene
      • 4.3.9.1. Propoxyphene market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.10. Others
      • 4.3.10.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Extended Release/Long-acting Opioids
    • 4.4.1. Extended release/Long-acting opioids market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Oxycodone
      • 4.4.2.1. Oxycodone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Hydrocodone
      • 4.4.3.1. Hydrocodone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. Methadone
      • 4.4.4.1. Methadone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. Fentanyl
      • 4.4.5.1. Fentanyl market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.6. Morphine
      • 4.4.6.1. Morphine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.7. Oxymorphone
      • 4.4.7.1. Oxymorphone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.8. Tapentadol
      • 4.4.8.1. Tapentadol market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.9. Buprenorphine
      • 4.4.9.1. Buprenorphine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.10. Hydromorphone
      • 4.4.10.1. Hydromorphone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.11. Others
      • 4.4.11.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. North America Opioids Market: Application Estimates & Trend Analysis

  • 5.1. North America Opioids Market: Key Takeaways
  • 5.2. North America Opioids Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Pain Relief
    • 5.3.1. Pain relief market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.2. Cancer Pain
      • 5.3.2.1. Cancer pain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.3. Post-Operative Care
      • 5.3.3.1. Post-operative care market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.4. Lower Back Pain
      • 5.3.4.1. Lower back pain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.5. Orthopedic
      • 5.3.5.1. Orthopedic market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.6. Neuropathic
      • 5.3.6.1. Neuropathic market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.7. Fibromyalgia
      • 5.3.7.1. Fibromyalgia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Anesthesia
    • 5.4.1. Anesthesia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Cough Suppression
    • 5.5.1. Cough suppression market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Diarrhea Suppression
    • 5.6.1. Diarrhea suppression market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. De-addiction
    • 5.7.1. De-addiction market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. North America Opioids Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. North America Opioids Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Purdue Pharma L.P.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Janssen Global Services, LLC
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Hikma Pharmaceuticals PLC
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Pfizer Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. AbbVie Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Sanofi
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Sun Pharmaceutical Industries Ltd.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Mallinckrodt Pharmaceuticals
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Endo Pharmaceuticals
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Teva Pharmaceutical Industries
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives